Outcome

This study found that Hyperbaric Oxygen Therapy (HBOT) significantly increased the proliferation of NIH3T3 fibroblasts and survival of spiral ganglion neurons (SGN) by enhancing the secretion of neuroprotective proteins like BDNF.

Introduction

In recent years hyperbaric oxygen therapy (HBOT) has garnered significant attention for its potential regenerative effects on the brain. This study shines a light on how HBOT could benefit patients with neurodegenerative diseases like Alzheimer’s by enhancing the levels of brain-derived neurotrophic factor (BDNF)—a vital protein for brain health. Researchers tested various pressures—1.0 1.5 and 2.0 bar—with fibroblasts and mesenchymal stem cells (MSCs) discovering intriguing results. While HBOT significantly boosted the proliferation of fibroblast cells and increased their production of neuroprotective proteins like Heat shock protein 70 and Thrombospondin-4 it did not have the same proliferative effect on MSCs at higher pressures. Additionally HBOT-treated cells promoted the survival of spiral ganglion neurons critical for hearing when exposed to conditioned mediums. These findings suggest HBOT could be a powerful adjunct in therapies aimed at brain plasticity and neuroprotection representing a promising frontier for treating cognitive decline and neurodegenerative disorders.

Results

The study investigated the effects of hyperbaric oxygen therapy (HBOT) on brain-derived neurotrophic factor (BDNF) release and neuroprotection in the context of Alzheimer’s Disease. Different oxygen pressures were tested: 1.0 ATA 1.5 ATA and 2.0 ATA with each treatment lasting 90 minutes. The study utilized fibroblasts and mesenchymal stem cells (MSCs) exposed to 5 and 10 treatments respectively.

The results showed that HBOT significantly enhanced the proliferation of NIH3T3 fibroblasts and genetically modified NIH3T3/BDNF fibroblasts but it did not increase and in some cases slightly reduced the proliferation of human MSCs at the highest pressure (2.0 bar). Despite this HBOT promoted the survival of spiral ganglion neurons (SGN) when treated with supernatants from both fibroblasts and MSCs. Notably in MSC cultures additional neuroprotective proteins like Heat shock protein 70 Thrombospondin-4 and Thioredoxin were produced under HBOT.

The experiment found that model cells like native and genetically modified fibroblasts showed a significant increase in proliferation after five days of HBOT compared to normoxic conditions. However MSCs treated at 2.0 bar had a decreased cell count. Additionally supernatants from HBO-treated cells improved SGN survival although HBOT itself did not directly influence this effect.

Overall the study concluded that HBOT enhances fibroblast proliferation alters the MSC secretome to include more neuroprotective proteins and supports neuron survival via secreted factors. These findings indicate that HBOT could be a promising adjuvant therapy in brain regenerative treatments and cell-based therapies for conditions like Alzheimer’s Disease. The research was funded by DFG Cluster of Excellence EXC 1077/1 “Hearing4all” and the authors declared no conflicts of interest.

Conclusion

In conclusion this study explores the impact of Hyperbaric Oxygen Therapy (HBOT) on brain-derived neurotrophic factor (BDNF) and its potential applications in brain regenerative therapies. By testing different HBOT conditions (1.0 bar 1.5 bar and 2.0 bar) the researchers have demonstrated significant increases in BDNF with HBOT sessions at 1.5 and 2.0 atmospheres. These sessions administered over 3 to 5 days indicate a strong potential for HBOT in fostering brain plasticity and regeneration which is crucial for individuals experiencing neurodegenerative diseases like Alzheimer’s Parkinson’s and Huntington’s.

The study also revealed that HBOT significantly enhanced the proliferation of fibroblasts particularly the genetically modified NIH3T3/BDNF cells but had a varied effect on human mesenchymal stem cells (MSCs) slightly reducing their proliferation at 2.0 atmospheres. Notably HBOT-treated fibroblasts and MSCs secreted factors that promoted the survival of spiral ganglion neurons (SGN). Furthermore HBOT modified the MSC secretome to include more proteins with neuroprotective potential such as Heat shock protein 70 Thrombospondin-4 and Thioredoxin.

These findings underscore HBOT’s promising role as an adjuvant therapy in cell-based treatments for neuroprotection and brain regeneration. By altering cell behavior and enhancing the production of neuroprotective proteins HBOT could provide significant clinical benefits for patients with neurological conditions. This study’s results encourage further exploration into HBOT’s applications in treating neurodegenerative diseases and enhancing the efficacy of regenerative therapies.